Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Braz. j. infect. dis ; 22(1): 51-54, Jan.-feb. 2018. tab, graf
Artículo en Inglés | LILACS, SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1039210

RESUMEN

ABSTRACT A retrospective cohort study, were evaluated: polymyxin B plus aminoglycosides or polymyxin B plus other antibiotics. Any degree of acute kidney injury occurred in 26 (86.6%) patients. The median time to acute kidney injury was 6.0 (95% CI 3-14) days in the polymyxin-aminoglycoside containing regimen group, against 27.0 (95% CI 6-42) days in the polymyxin with other antimicrobial combinations group (p = 0.03). Polymyxin B with aminoglycosides group progressed faster to any degree of renal dysfunction.


Asunto(s)
Humanos , Masculino , Femenino , Polimixina B/uso terapéutico , Infecciones por Enterobacteriaceae/tratamiento farmacológico , Riñón/efectos de los fármacos , Mediastinitis/microbiología , Mediastinitis/tratamiento farmacológico , Antibacterianos/uso terapéutico , Pruebas de Sensibilidad Microbiana , Carbapenémicos/farmacología , Estudios Retrospectivos , Resultado del Tratamiento , Estadísticas no Paramétricas , Medición de Riesgo , Resistencia betalactámica/efectos de los fármacos , Infecciones por Enterobacteriaceae/mortalidad , Estimación de Kaplan-Meier , Lesión Renal Aguda/inducido químicamente , Aminoglicósidos/uso terapéutico , Mediastinitis/mortalidad
3.
Braz J Infect Dis ; 22(1): 51-54, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29182906

RESUMEN

A retrospective cohort study, were evaluated: polymyxin B plus aminoglycosides or polymyxin B plus other antibiotics. Any degree of acute kidney injury occurred in 26 (86.6%) patients. The median time to acute kidney injury was 6.0 (95% CI 3-14) days in the polymyxin-aminoglycoside containing regimen group, against 27.0 (95% CI 6-42) days in the polymyxin with other antimicrobial combinations group (p=0.03). Polymyxin B with aminoglycosides group progressed faster to any degree of renal dysfunction.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones por Enterobacteriaceae/tratamiento farmacológico , Riñón/efectos de los fármacos , Mediastinitis/tratamiento farmacológico , Mediastinitis/microbiología , Polimixina B/uso terapéutico , Lesión Renal Aguda/inducido químicamente , Aminoglicósidos/uso terapéutico , Carbapenémicos/farmacología , Infecciones por Enterobacteriaceae/mortalidad , Femenino , Humanos , Estimación de Kaplan-Meier , Masculino , Mediastinitis/mortalidad , Pruebas de Sensibilidad Microbiana , Estudios Retrospectivos , Medición de Riesgo , Estadísticas no Paramétricas , Resultado del Tratamiento , Resistencia betalactámica/efectos de los fármacos
4.
Transpl Infect Dis ; 16(1): 135-40, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24383613

RESUMEN

Trichosporon species are rare etiologic agents of invasive fungal infection in solid organ transplant (SOT) recipients. We report 2 well-documented cases of Trichosporon inkin invasive infection in SOT patients. We also conducted a detailed literature review of Trichosporon species infections in this susceptible population. We gathered a total of 13 cases of Trichosporon species infections. Any type of organ transplantation can be complicated by Trichosporon infection. Bloodstream infections and disseminated infections were the most common clinical presentations. Liver recipients with bloodstream or disseminated infections had poor prognoses. Although the most common species was formerly called Trichosporon beigelii, this species name should no longer be used because of the changes in the taxonomy of this genus resulting from the advent of molecular approaches, which were also used to identify the strains isolated from our patients. Antifungal susceptibility testing highlights the possibility of multidrug resistance. Indeed, Trichosporon has to be considered in cases of breakthrough infection or treatment failure under echinocandins or amphotericin therapy. Voriconazole seems to be the best treatment option.


Asunto(s)
ADN de Hongos/análisis , Empiema/inmunología , Rechazo de Injerto/prevención & control , Trasplante de Corazón , Huésped Inmunocomprometido , Inmunosupresores/uso terapéutico , Enfermedades Pulmonares Fúngicas/inmunología , Trasplante de Pulmón , Mediastinitis/inmunología , Pericarditis/inmunología , Trichosporon/genética , Tricosporonosis/inmunología , Adulto , Antifúngicos/uso terapéutico , ADN Intergénico/análisis , ADN Ribosómico/análisis , Farmacorresistencia Fúngica , Empiema/diagnóstico , Empiema/tratamiento farmacológico , Humanos , Enfermedades Pulmonares Fúngicas/diagnóstico , Enfermedades Pulmonares Fúngicas/tratamiento farmacológico , Masculino , Mediastinitis/diagnóstico , Mediastinitis/tratamiento farmacológico , Pruebas de Sensibilidad Microbiana , Pericarditis/diagnóstico , Pericarditis/tratamiento farmacológico , Derrame Pleural/diagnóstico , Derrame Pleural/tratamiento farmacológico , Derrame Pleural/inmunología , Pirimidinas/uso terapéutico , Análisis de Secuencia de ADN , Triazoles/uso terapéutico , Tricosporonosis/diagnóstico , Tricosporonosis/tratamiento farmacológico , Voriconazol , Adulto Joven
5.
J Surg Res ; 185(1): 64-9, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23809152

RESUMEN

BACKGROUND: We aimed to investigate the influence of intraperitoneal ozone therapy on bacterial elimination and mediastinal inflammation in experimental Staphylococcus aureus mediastinitis. MATERIALS AND METHODS: Forty Wistar-Albino rats were randomized into five groups (eight per group) as follows: uncontaminated group, untreated contaminated group, ozone group, vancomycin group, and vancomycin + ozone group. Uncontaminated group underwent upper median sternotomy. The remaining four groups were inoculated with 0.5 mL 10(8) colony-forming units/mL methicillin-resistant Staphylococcus aureus in the mediastinal and sternal layers. Untreated contaminated group had no treatment. Rats in the vancomycin group received intramuscular vancomycin (40 mg/kg/d), and ozone was administered intraperitoneally (70 µg/mL, 1 mg/kg/d) in the ozone group for the treatment of mediastinitis. Vancomycin + ozone group rats were treated by the combination of both methods. At the end of 10 d, quantitative bacterial cultures and sternal tissue samples were obtained for determination of bacterial counts and histologic degree of inflammation. RESULTS: Both the vancomycin and the ozone treatments caused significant reduction of bacterial counts in quantitative bacterial cultures. Combination of vancomycin and ozone treatments resulted in further reduction of bacterial counts in mediastinum and sternum. Histologic examination of tissue samples revealed significant reduction in severity of mediastinitis related inflammation in vancomycin and vancomycin + ozone groups compared with untreated contaminated group. CONCLUSIONS: Ozone therapy as an adjunct to vancomycin leads to enhanced bacterial elimination in infected sternal and mediastinal tissues in experimental methicillin-resistant Staphylococcus aureus mediastinitis. The benefit of adjuvant ozone therapy is suggested to be related to its bactericidal effect.


Asunto(s)
Mediastinitis/tratamiento farmacológico , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Ozono/farmacología , Infecciones Estafilocócicas/tratamiento farmacológico , Esternón/microbiología , Vancomicina/farmacología , Animales , Antibacterianos/farmacología , Terapia Combinada , Modelos Animales de Enfermedad , Humanos , Mediastinitis/microbiología , Staphylococcus aureus Resistente a Meticilina/crecimiento & desarrollo , Distribución Aleatoria , Ratas , Ratas Wistar , Infecciones Estafilocócicas/microbiología , Esternón/cirugía , Infección de la Herida Quirúrgica/tratamiento farmacológico , Infección de la Herida Quirúrgica/microbiología , Resultado del Tratamiento
6.
Ann Thorac Surg ; 78(2): 608-12; discussion 608-12, 2004 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15276531

RESUMEN

BACKGROUND: Wound infection after median sternotomy for cardiac or thoracic surgery is a serious complication. A variety of treatment plans have been advocated, and there is lack of agreement regarding the best treatment method. We present our results in patients with mediastinitis who have been treated in a simple, consistent manner. METHODS: We reviewed our experience with 40 consecutive patients with mediastinitis who were treated between January 1995 and May 2003 with a single-stage treatment consisting of sternal and soft tissue debridement and wound closure over mediastinal tubes with continuous irrigation and drainage. Tubes were placed posterior to the sternum in all patients and were irrigated continuously for at least 7 days with antibiotic or antibacterial solution. Systemic antibiotics were selected based on culture and sensitivity data and were administered for 2 to 6 weeks. RESULTS: All patients with mediastinitis treated in this manner survived. Of the 40 patients, 38 achieved complete healing of the wound without further operative intervention or major complication. One patient had recurrent infection and required sternal resection and advancement of muscle flaps. One patient had a residual localized focus of chondritis and underwent limited resection of cartilage. CONCLUSIONS: In this series of patients with postoperative mediastinitis, a simplified approach consisting of wound debridement, reclosure over drains, and anterior mediastinal irrigation has been an effective treatment. The results we have achieved suggest that this technique may be a suitable option for treating this condition.


Asunto(s)
Antibacterianos , Desbridamiento , Quimioterapia Combinada/uso terapéutico , Mediastinitis/cirugía , Infecciones Estafilocócicas/cirugía , Esternón/cirugía , Succión , Infección de la Herida Quirúrgica/cirugía , Irrigación Terapéutica , Adulto , Anciano , Candidiasis/tratamiento farmacológico , Candidiasis/cirugía , Tubos Torácicos , Terapia Combinada , Quimioterapia Combinada/administración & dosificación , Femenino , Humanos , Huésped Inmunocomprometido , Masculino , Mediastinitis/tratamiento farmacológico , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Estudios Retrospectivos , Infecciones Estafilocócicas/tratamiento farmacológico , Infección de la Herida Quirúrgica/tratamiento farmacológico , Procedimientos Quirúrgicos Torácicos
8.
Clin Infect Dis ; 30(4): 688-95, 2000 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10770731

RESUMEN

OBJECTIVE: The objective of this guideline is to provide recommendations for treating patients with the more common forms of histoplasmosis. PARTICIPANTS AND CONSENSUS PROCESS: A working group of 8 experts in this field was convened to develop this guideline. The working group developed and refined the guideline through a series of conference calls. OUTCOMES: The goal of treatment is to eradicate the infection when possible, although chronic suppression may be adequate for patients with AIDS and other serious immunosuppressive disorders. Other important outcomes are resolution of clinical abnormalities and prevention of relapse. EVIDENCE: The published literature on the management of histoplasmosis was reviewed. Controlled trials have been conducted that address the treatment of chronic pulmonary and disseminated histoplasmosis, but clinical experience and descriptive studies provide the basis for recommendations for other forms of histoplasmosis. VALUE: Value was assigned on the basis of the strength of the evidence supporting treatment recommendations, with the highest value assigned to controlled trials, according to conventions established for developing practice guidelines. BENEFITS AND COSTS: Certain forms of histoplasmosis cause life-threatening illnesses and result in considerable morbidity, whereas other manifestations cause no symptoms or minor self-limited illnesses. The nonprogressive forms of histoplasmosis, however, may reduce functional capacity, affecting work capacity and quality of life for several months. Treatment is clearly beneficial and cost-effective for patients with progressive forms of histoplasmosis, such as chronic pulmonary or disseminated infection. It remains unknown whether treatment improves the outcome for patients with the self-limited manifestations, since this patient population has not been studied. Other chronic progressive forms of histoplasmosis are not responsive to pharmacologic treatment. TREATMENT OPTIONS: Options for therapy for histoplasmosis include ketoconazole, itraconazole, fluconazole, amphotericin B (Fungizone; Bristol-Meyer Squibb, Princeton, NJ), liposomal amphotericin B (AmBisome; Fujisawa, Deerfield, IL), amphotericin B colloidal suspension (ABCD, or Amphotec; Seques, Menlo Park, CA), and amphotericin B lipid complex (ABLC, or Abelcet; Liposome, Princeton, NJ).


Asunto(s)
Antifúngicos/uso terapéutico , Histoplasmosis/tratamiento farmacológico , Artritis/tratamiento farmacológico , Artritis/microbiología , Enfermedades del Sistema Nervioso Central/tratamiento farmacológico , Enfermedades del Sistema Nervioso Central/microbiología , Análisis Costo-Beneficio , Femenino , Directrices para la Planificación en Salud , Histoplasma/efectos de los fármacos , Histoplasmosis/economía , Histoplasmosis/transmisión , Humanos , Enfermedades Pulmonares/tratamiento farmacológico , Mediastinitis/tratamiento farmacológico , Mediastinitis/microbiología , Evaluación de Resultado en la Atención de Salud , Pericarditis/tratamiento farmacológico , Pericarditis/microbiología , Embarazo , Complicaciones del Embarazo
9.
J Antimicrob Chemother ; 21 Suppl A: 93-103, 1988 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-2965137

RESUMEN

A total of 88 patients were treated with teicoplanin for infections caused by coagulase-negative staphylococci in open clinical studies in France and the UK. Teicoplanin was administered once daily, with a mean dose of 323 mg, for a mean duration of 16 days. Thirty-nine patients received teicoplanin alone while 49 received combination treatment. Clinical cure or improvement occurred in 79 of 82 evaluable cases (96.3%) and bacteriological elimination in 82 cases (95.1%). Treatment with teicoplanin alone was clinically successful in all cases, including 20 septicaemias, and the elimination rate was 93%. There was no apparent correlation between clinical and bacteriological outcomes and results of in-vitro testing. The variation in MICs between France and the UK was attributed to differences in the methods used.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones Estafilocócicas/tratamiento farmacológico , Adolescente , Adulto , Anciano , Antibacterianos/efectos adversos , Artritis Infecciosa/tratamiento farmacológico , Coagulasa/metabolismo , Quimioterapia Combinada , Glicopéptidos/efectos adversos , Glicopéptidos/uso terapéutico , Humanos , Mediastinitis/tratamiento farmacológico , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Osteítis/tratamiento farmacológico , Sepsis/tratamiento farmacológico , Enfermedades Cutáneas Infecciosas/tratamiento farmacológico , Infecciones Estafilocócicas/microbiología , Staphylococcus/efectos de los fármacos , Staphylococcus/enzimología , Teicoplanina , Infecciones Urinarias/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA